

5-[1-(3,4-Dichlorophenoxy)ethyl]-1,3,4-oxadiazole-2(3H)-thione hemihydrate

Tashfeen Akhtar,^a M. Khawar Rauf,^a Shahid Hameed^{a*} and Xiaoming Lu^b

^aDepartment of Chemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan,

and ^bDepartment of Chemistry, Capital Normal University, Beijing Taiyuan 100037,

People's Republic of China

Correspondence e-mail: shameed@qau.edu.pk

Received 11 July 2009; accepted 28 July 2009


Key indicators: single-crystal X-ray study; $T = 123\text{ K}$; mean $\sigma(\text{C}-\text{C}) = 0.002\text{ \AA}$;

R factor = 0.027; wR factor = 0.078; data-to-parameter ratio = 19.1.

In the title compound, $\text{C}_{10}\text{H}_8\text{Cl}_2\text{N}_2\text{O}_2\text{S}\cdot0.5\text{H}_2\text{O}$, the atoms in the oxadiazole ring are essentially coplanar (r.m.s. deviation 0.010 \AA). The crystal structure is stabilized by intermolecular $\text{N}-\text{H}\cdots\text{O}$ hydrogen bonds involving the water molecule, which is situated on an a twofold rotation axis, and two organic molecules, leading to a thione tautomer in the solid state. The C atom attached to the oxadiazole ring adopts a typical sp^3 hybridization. The dihedral angle between the mean plane of the benzene ring of the dichlorophenyl group and the mean plane of the oxadiazole ring is $74.18(4)^\circ$. The crystal structure is stabilized by intermolecular $\text{N}-\text{H}\cdots\text{O}$ and $\text{O}-\text{H}\cdots\text{S}$ hydrogen bonds.

Related literature

For the structures and properties of oxadiazoles, see: Almasirad *et al.* (2004); Aboraia *et al.* (2006); Akhtar, Hameed, Al-Masoudi *et al.* (2008); Khan *et al.* (2005); Akhtar, Hameed *et al.* (2007); Akhtar, Hameed, Khan *et al.* (2008); Akhtar, Rauf *et al.* (2007); Aydogan *et al.*, 2002). For a related structure, see: Thamotharan *et al.* (2005). For bond-length data, see: Allen *et al.* (1987).



Experimental

Crystal data

$\text{C}_{10}\text{H}_8\text{Cl}_2\text{N}_2\text{O}_2\text{S}\cdot0.5\text{H}_2\text{O}$	$V = 2490.38(6)\text{ \AA}^3$
$M_r = 300.15$	$Z = 8$
Monoclinic, $C2/c$	Mo $K\alpha$ radiation
$a = 11.8725(2)\text{ \AA}$	$\mu = 0.68\text{ mm}^{-1}$
$b = 7.89320(10)\text{ \AA}$	$T = 123\text{ K}$
$c = 26.6092(4)\text{ \AA}$	$0.40 \times 0.30 \times 0.25\text{ mm}$
$\beta = 92.9130(10)^\circ$	

Data collection

Bruker SMART CCD area-detector diffractometer	3088 independent reflections
Absorption correction: none	2490 reflections with $I > 2\sigma(I)$
10568 measured reflections	$R_{\text{int}} = 0.019$

Refinement

$R[F^2 > 2\sigma(F^2)] = 0.027$	H atoms treated by a mixture of independent and constrained refinement
$wR(F^2) = 0.078$	$\Delta\rho_{\text{max}} = 0.22\text{ e \AA}^{-3}$
$S = 1.09$	$\Delta\rho_{\text{min}} = -0.21\text{ e \AA}^{-3}$
3088 reflections	
162 parameters	

Table 1
Hydrogen-bond geometry (\AA , $^\circ$).

$D-\text{H}\cdots A$	$D-\text{H}$	$\text{H}\cdots A$	$D\cdots A$	$D-\text{H}\cdots A$
N1—H1···O1W	0.86	2.06	2.9084 (16)	168
O1W—H1W···S1 ⁱ	0.846 (17)	2.612 (18)	3.3854 (13)	152.5 (17)

Symmetry code: (i) $x + \frac{1}{2}, y + \frac{1}{2}, z$.

Data collection: *SMART* (Bruker, 2007); cell refinement: *SAINT* (Bruker, 2007); data reduction: *SAINT*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 2008); program(s) used to refine structure: *SHELXL97* (Sheldrick, 2008); molecular graphics: *ORTEP-3* (Farrugia, 1997) and *Mercury* (Macrae *et al.*, 2006); software used to prepare material for publication: *SHELXTL* (Sheldrick, 2008).

The authors are grateful to Professor G. B. Jameson, Institute of Fundamental Sciences, Private Bag 11 222, Massey University, Palmerston North, New Zealand, for fruitful discussions.

Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: SU2129).

References

- Aboraia, A. S., Abdel-Rahman, H. M., Mahfouz, N. M. & El-Gendy, M. A. (2006). *Bioorg. Med. Chem.* **14**, 1236–1246.
- Akhtar, T., Hameed, S., Al-Masoudi, N. A. & Khan, K. M. (2007). *Heteroat. Chem.* **18**, 316–322.
- Akhtar, T., Hameed, S., Al-Masoudi, N. A., Loddo, R. & La Colla, P. (2008a). *Acta Pharm.* **58**, 135–149.
- Akhtar, T., Hameed, S., Khan, K. M. & Choudhary, M. I. (2008b). *Med. Chem.* **4**, 539–543.
- Akhtar, T., Khawar Rauf, M., Ebihara, M. & Hameed, S. (2007). *Acta Cryst. E63*, o2590–o2592.
- Allen, F. H., Kennard, O., Watson, D. G., Brammer, L., Orpen, A. G. & Taylor, R. (1987). *J. Chem. Soc. Perkin Trans. 2*, pp. S1–19.
- Almasirad, A., Tabatabai, S. A., Faizi, M., Kebriaeezade, A., Mehrabi, N., Dalvandi, A. & Shafiee, A. (2004). *Bioorg. Med. Chem. Lett.* **14**, 6057–6059.
- Aydogan, F., Turgut, Z., Ocal, N. & Erdem, S. S. (2002). *Turk. J. Chem.* pp. 159–163.

organic compounds

- Bruker (2007). *SMART* and *SAINT*. Bruker AXS Inc., Madison, Wisconsin, USA.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Khan, M. T. H., Choudhary, M. I., Khan, K. M., Rani, M. & Rahman, A. (2005). *Bioorg. Med. Chem.* **13**, 3385–3395.
- Macrae, C. F., Edgington, P. R., McCabe, P., Pidcock, E., Shields, G. P., Taylor, R., Towler, M. & van de Streek, J. (2006). *J. Appl. Cryst.* **39**, 453–457.
- Sheldrick, G. M. (2008). *Acta Cryst. A* **64**, 112–122.
- Thamotharan, S., Parthasarathi, V., Anandha Babu, G., Hunnur, R. K., Badami, B. & Linden, A. (2005). *Acta Cryst. E* **61**, o3746–o3747.